TME Pharma NV (FRA:0N6A) Total Assets : €2.94 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is TME Pharma NV Total Assets?

TME Pharma NV's Total Assets for the quarter that ended in Jun. 2024 was €2.94 Mil.

During the past 12 months, TME Pharma NV's average Total Assets Growth Rate was -47.40% per year. During the past 3 years, the average Total Assets Growth Rate was -8.60% per year. During the past 5 years, the average Total Assets Growth Rate was 5.70% per year.

During the past 10 years, TME Pharma NV's highest 3-Year average Total Assets Growth Rate was 20.50%. The lowest was -51.10%. And the median was -8.60%.

Total Assets is connected with ROA %. TME Pharma NV's annualized ROA % for the quarter that ended in Jun. 2024 was -239.13%. Total Assets is also linked to Revenue through Asset Turnover. TME Pharma NV's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.

TME Pharma NV Total Assets Historical Data

The historical data trend for TME Pharma NV's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Total Assets Chart

TME Pharma NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

1.73

10.65

9.77

5.24

2.49

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Assets	Get a 7-Day Free Trial														8.28	5.24	3.46	2.49	2.94

TME Pharma NV Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

TME Pharma NV's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-0.294	+	2.785
	=	2.49

TME Pharma NV's Total Assets for the quarter that ended in Jun. 2024 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2024 )	+	Total Liabilities (Q: Jun. 2024 )
	=	1.567	+	1.375
	=	2.94

TME Pharma NV (FRA:0N6A) Total Assets Explanation

Total Assets is connected with ROA %.

TME Pharma NV's annualized ROA % for the quarter that ended in Jun. 2024 is

ROA %	=	Net Income (Q: Jun. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
	=	-6.496	/	( (2.491	+	2.942)	/ 2 )
	=	-6.496	/	2.7165
	=	-239.13 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

TME Pharma NV's Asset Turnover for the quarter that ended in Jun. 2024 is

	Asset Turnover
=	Revenue (Q: Jun. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
=	0	/	( (2.491	+	2.942)	/ 2 )
=	0	/	2.7165
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

TME Pharma NV Total Assets Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ALTME:France

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines